Early Combination Therapy in the Treatment of Type 2 Diabetes


This webcast will cover the current guideline recommendations for the treatment of type 2 diabetes and will review the benefits and risks of various classes of antihyperglycemic agents including SGLT-2 inhibitors, discuss considerations for early combination therapy, and strategies for reducing clinical inertia. 

Target Audience
This CME initiative was designed for nurse practitioners, physician assistants, and primary care providers working in diabetes care. 

Learning Objectives
  1. Review current guideline recommendations for the initiation and intensification of therapy in patient with type 2 diabetes
  2. Discuss the benefits and risks of various classes of antihyperglycemic agents
  3. Discuss clinical considerations for early combination therapy
  4. Implement strategies to reduce clinical inertia in the treatment of patients with type 2 diabetes

Activity Launch Date - 12/4/18
Expiration Date - 12/4/19

Supporter Acknowledgment Statement
This activity is supported by an independent educational grant from Merck.

Disclosure of Unlabeled Use
This educational activity may contain 
discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies.  It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes.  To that end, we welcome comments about how to better serve your needs.

Copyright Information
© 2018 by Horizon CME.  All rights reserved.  No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.